PlantForm and PharmaPraxis establish joint venture for biosimilars/biobetters

June 27, 2014 7:34 AM

PlantForm Corporation of Canada and PharmaPraxis of Brazil have announced the establishment of a joint venture to develop, manufacture and commercialize biosimilar and/or biobetter versions of six key biopharmaceuticals for the Brazilian market, using PlantForm’s lowcost manufacturing system.

The joint venture will first develop a biosimilar/biobetter version of the oncology drug Avastin (bevacizumab), in collaboration with the Fraunhofer Center for Molecular Biology in Newark, Delaware, USA, which will produce the active pharmaceutical ingredient (API) for clinical trials.

Brazilian government corporation Bio-Manguinhos will also participate in the project. Bio-Manguinhos is responsible for technology development and production of vaccines, reagents and biopharmaceuticals to meet public health demands.

The joint venture will build a pilot cGMP biopharmaceutical manufacturing facility in Brazil.

“PharmaPraxis is pleased to establish this joint venture to bring PlantForm’s innovative, plant based manufacturing system to Brazil,” said PharmaPraxis CEO Eduardo Cruz. “We aim to significantly reduce the cost of important biopharmaceuticals in order to make these medications more widely available.”

“This joint venture agreement with PharmaPraxis and the support of the Brazilian government is a significant milestone for PlantForm,” said Dr. Don Stewart, PlantForm’s President and CEO. “It advances our global strategy for biosimilar drug development and manufacturing, and we look forward to a highly productive and long-term collaboration.”

“Bio-Manguinhos is investing in Brazil’s biopharmaceutical production capacity, and we are keenly interested in this plant-based technology project and anticipate future engagement,” said Artur Couto, Bio-Manguinhos Director.


Source: PlantForm press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!